Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2009

View Archived Issues

Recent Georgia Tech patent describes novel HDAC inhibitors

New MAPKAP-K2 (MK2) inhibitors reported in recent Novartis patent

Combination of YM-155, docetaxel and prednisone used in prostate cancer therapy

BIBF-1120 and BIBW-2992 may be used in combination in prostate cancer treatment

Bayer discloses prodrugs of apixaban for thromboembolic disorders

Merck & Co. discloses novel orexin receptor antagonists for insomnia

New HCV NS3/NS4 protease inhibitors reported in recent Gilead patent

PharmaMar licenses kahalalide F analogues to Marinomed

Catalyst halts enrollment into phase II trial of CPP-109 for methamphetamine addiction

MMI presents update on clinical development of GVX-3322 and ONCO-4417

2008 highlights at Elan

Anacor reports encouraging results from phase I AN-2718 trial

Pharmexa and Affitech enter into conditional merger agreement

MDV-3100 displays safety and antitumor activity in phase I/II trial for prostate cancer

Vertex to acquire ViroChem and its preclinical-stage polymerase inhibitors

FDA gives positive review of InNexus' IND plans for DXL-625 in NHL and CLL

Dronedarone reduces risk of hospitalization from cardiovascular events in atrial fibrillation

Meropenem/clavulanate combination inhibits extensively drug-resistant tuberculosis

Ferring launches degarelix for advanced prostate cancer

Quest presents positive results for its photosensitizer SL-052

4SC initiates phase IIa trial for 4SC-101 in Crohn's disease

Access announces results from a phase II ovarian cancer trial of ProLindac

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

GlaxoSmithKline submits MAA for pazopanib in advanced kidney cancer

NICE refuses funding for advanced breast cancer treatment, Tyverb

Proteon initiates phase I/II PRT-201 study in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....